His Royal Highness Prince Michael of Kent GCVO Visits Beijing and Shows Support to Improving Healthcare Standards in China; Medicsight Introduces Cancer Diagnostic Guidelines for CAD Chest CT and CAD CTC.

BEIJING -- Medicsight Inc.'s (AMEX:MGT) majority owned subsidiary, Medicsight PLC ("Medicsight"), introduced guidelines for Chest CT and CTC to top international radiology and oncology experts from China and the UK at a board meeting today. Attending the session was His Royal Highness Prince Michael of Kent GCVO, patron of the Medicsight Foundation.

The meeting positioned Medicsight as the medical imaging market leader in facilitating the use of computed tomography in the detection and diagnosis of lung and colorectal cancer. The guidelines received endorsements from Chinese luminaries in the radiology and oncology fields, including Professor Ma Daqing, Chief Radiologist, Beijing Friendship Hospital and President of the Chinese Radiology Society; Professor Zhou Chunwu, Vice President of the Cancer Institute and Director of the Department of Diagnostic Radiology, Chinese Academy of Medical Sciences, Peking Union Medical College; Professor Chen Qihang, Vice Chairman of the Department of Radiology, Beijing Hospital, Peking University Health Sciences; and professor Zhou Cheng, Vice President of the Department of Diagnostic Radiology, Peking Union Medical College Hospital.

"The economic miracle taking place in China is helping to significantly raise healthcare standards for many of China's citizens. I see tremendous opportunity for British companies participating with China to improve the country's economy and healthcare offerings. The transfer of leading-edge technology, such as Medicsight's CAD products, play an important role in this effort. These guidelines represent a milestone for healthcare in China," said His Royal Highness Prince Michael of Kent GCVO.

"These guidelines for chest CT are widely accepted and practiced by radiologists in the West. At the recent National CSR Chest Meeting in Zhengzhou, we were extremely pleased that the guidelines were recognized and adopted in the collection of thesis compiled by the Chinese Society of Radiology," said David Sumner, the CEO for Asia-Pacific, Medicsight.

David Sumner added, "The Medicsight CAD products will be available via www.medicexchange.com, the world's first medical imaging portal that provides both software solutions and clinical information in the China market later this year. MedicExchange will offer both the Medicsight CAD products and an unparalleled range of medical imaging software tools and associated clinical services from around the world in one place. I firmly believe that doctors and the radiologists will be benefit tremendously from the CAD and its unique online distribution partner."

Sumner continued, "The guidelines highlight the importance of conducting regular check ups. The early identification of diseases significantly improves the chances of successful treatment and cure. MDCT combined with CAD technology, will help doctors manage information and enhance the workflow experience and diagnostic accuracy of physicians at all levels of patient management."

Medicsight develops enterprise-wide computer-aided detection (CAD) software available via www.medicexchange.com on a fee-per-study basis that is used by the medical imaging market to aid in earlier detection of disease. Tested on one of the world's largest and most population diverse databases of verified CT scan data, Medicsight's software solutions help clinicians identify, measure, and analyze suspicious pathology, such as colorectal polyps and lung lesions. The company's CAD products include ColonCAD available for CT colonography, and LungCAD available for Chest CT. Both products include a concurrent-read feature that allows clinicians to review the original image simultaneously with the Medicsight CAD findings, which results in improved workflow and productivity. Medicsight continues to develop CAD software for a variety of disease states that can help in the early detection of disease and ultimately improve patient outcomes. Headquartered in London, Medicsight employs more than 70 people and also has offices in the United States, Japan, China, and Gibraltar. Product and company information can be found on www.medicsight.com. Stock symbol: MGT